New pediatric diagnostic and therapeutic procedure · cancer surgery, including breast...

Ref: TRUK20140602001 of 19

Printed: 25 June 2014

Technology Offer

New pediatric diagnostic and therapeutic procedure

Summary

A Hungarian SME has developed a special tool for the movement therapy of brain injured children. The patented hemisphere-like tool, can improve the balance ability of affected children. It is an efficient, comfortable and safe development three function device (diagnosis, therapy and toy) substituting several instruments thus saving costs, place and time. The company is looking for partners for technical cooperation.

Creation Date 20 July 2015

Last Update 24 July 2015

Expiration Date 23 July 2016

Reference TOHU20150720001

Details

Description

The Hungarian SME is offering a new diagnostic and movement therapy device that influences the functioning of the central nervous system through the balance system. This device is suitable for diagnosis, treatment and development of children with special needs arising from having born with central nervous disorders. The mechanism of action of device is based on the targeted stimulation of the vestibular system. This new device serves the examination of the adaptive responses to the stimulation of the vestibular system. The nystagmus and the response reactions of movement control to the spatial stimuli are assessed. The device allows throughout the examination for a smooth and child-friendly screening for differences in the central nervous system maturity, persistent primitive and pathologic reflexes, asymmetries and alterations in balance and coordination. The regular use of device in the early therapy of nervous system disorders may significantly improve the movement control. The hemisphere shaped tool helps instructors in playfully assessing and improving the balance ability of children. Sitting in the device is a complex task requiring the coordinated movement of the trunk and muscles around the pelvic grindle. This task in itself has beneficial effect. - Its therapeutic effects: - Initiation of sensorial sensations and motor functions - Motor development planning, cortical function improvement, eye-hand coordination and space orientation - Development of cognitive abilities - Positive reinforcement of the psychological attitudes. Partners for technical cooperation are expected for application of the device. Partner (rehabilitation

Ref: TRUK20140602001 of 19


centers) can implement the developed therapy into their own procedures with the help of consultancy services provided by the Hungarian partner.

Advantages and Innovations

The multifunctional device can fulfil the following tasks: - It integrates the use of several devices resulting in the reduction of cost, place and therapy time. - it provides 3D movements - It is an efficient, comfortable and safe development tool offering a more successful therapy - It is the only one qualified as a medical device - It has a professional training background - It may be already used practically from birth, for 0 – 6 months old babies up to adulthood

- It diagnoses the altered neurological development process in the brain already in early babyhood. - It offers a comprehensive, multi-phase therapy giving full recovery in case of a smaller problem and a significant improvement in case of a more important brain injury. - It offers also prevention, as with the rolling of the new-born baby the integration process can be launched, reinforced, therefore the risk of all later development disorders may be reduced. This is of high importance for premature babies. - It may be used for scientific purposes as well. - It proves beneficial as a development tool of psycho-social-cognitive abilities as well. - It can also be used in water, its hydrotherapic application renders the curing process even more efficient. It doesn’t sink even if it is filled up with water and with a child inside.

In comparison with the existing device on the market it is the only device that may be used preserving its efficiency both in dry and wet conditions for children and adults alike. It offers a more delicate balancing, tilting and rolling movement, therefore it can be used without supervision.

Stage of Development

Already on the market

IPR Status

Patents granted

Comment Regarding IPR status

The device is patented in the EU and the US.

Profile Origin

Private (in-house) research

Keywords

Technology

006001006 Diagnostics, Diagnosis

006001017 Physiology

006001022 Physiotherapy, Orthopaedic Technology

Market

005001001 Diagnostic services

005002001 Therapeutic services

005008001 Patient rehabilitation & training

Ref: TRUK20140602001 of 19


NACE

M.72.1.9 Other research and experimental development on natural sciences and engineering

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

0

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English

Client Country

Hungary

Partner Sought

Type and Role of Partner Sought

- Type of partner sought: public or private rehabilitation centers. Specific area of activity of the partner: rehabilitation, umbrella organization that is in connection with development institutions - Task to be performed: Looking for technical cooperation. The partner should be able to apply the device, along with the specified therapy and consultancy services provided by the Hungarian partner.

Type of Partnership Considered

Technical cooperation agreement

Ref: TRUK20140602001 of 19


Technology Offer

Compounds for the treatment of the orphan myotonic dystrophy type 1 disease

Summary

Spanish researchers have proved the use of certain compounds for the prevention and/or treatment of myotonic dystrophy type 1, a rare disease with no curative pharmacological treatment. These compounds are commercially available and employed to treat other pathologies, so their side effects are known. The invention is patent pending. The researchers are looking for license agreement with health and pharmaceutical companies, which is patent pending. They are also open to technical collaborations.

Creation Date 29 June 2015



Reference TOES20150629001

Details

Description

The myotonic dystrophy type 1 (DM1; OMIM 160900, Steinert disease) is a hereditary autosomal dominant, chronic multisistemic disease that affects mainly the muscles of the body (including the heart) and the central nervous system, with the corresponding wasting of the muscular mass. It is the most common form of muscular dystrophy in adults, with an estimated prevalence of 1 every 8.000. Due to the impact of the so called rare diseases in public health and that there is no curative pharmacological treatment for this pathology, there is a need to find effective drugs for the treatment of severe congenital myotonic dystrophy type 1 and adult-onset myotonic dystrophy type 1. Spanish researchers have proved the use in the prevention and/or treatment of myotonic dystrophy type 1 of certain compounds, and sales thereof, which reduce the autophagy and apoptosis levels which are elevated in the skeletal musculature of patients with myotonic dystrophy type 1 compared to normal subjects. The effectivity of the compounds has been tested in vivo in an inducible Drosophila model and cellular models of the disease. The main application of the technology is in the pharmaceutical field, as a drug or active principle for the prevention and/or treatment of myotonic dystrophy type 1. The main advantage of the invention is that the majority of the tested compounds are compounds already used in the clinical practice to treat other pathologies not related to myotonic dystrophies so that their adverse effects and pharmacology are known.

Ref: TRUK20140602001 of 19


The researchers are looking for specific partners of pharmaceutical business committed to the treatment of rare muscular disorders through innovative research and technology for licensing the invention and for technical cooperation agreements (i.e. testing of applications, adaptation to specific needs, production and marketing).


The most innovative aspect of this technology is that there is currently no effective treatment for the muscle atrophy phenotype in myotonic dystrophy patients, which is a critical aspect of the disease because leads to severe disability and is the leading cause of death due to respiratory distress. The main advantage provided by the technology is to significantly facilitate translation to the clinical setting because of the repositioning of a currently marketed drug to treat a new medical condition. Furthermore, one of the candidate drugs is particularly well tolerated in humans.


Under development/lab tested

IPR Status

Patent(s) applied for but not yet granted


European patent applied for but not yet granted

Profile Origin

Other

Keywords

Technology

006001016 Pharmaceutical Products / Drugs

Market

005003002 Pharmaceuticals/fine chemicals

NACE

P.85.4.2 Tertiary education

Dissemination


Healthcare

Ref: TRUK20140602001 of 19


Client


University

Year Established

0


No.

Languages Spoken

English Spanish

Client Country

Spain

Partner Sought


- Type of partner sought: Enterprise - Specific area of activity of the partner: drug manufacturers and pharma-industry in general through innovative research and technology - Task to be performed: licensing the invention, testing of applications, adaptation to specific needs, production and marketing.

Type and Size of Partner Sought

SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500


License agreement Technical cooperation agreement

Ref: TRUK20140602001 of 19


Technology Offer

Low cost 3D scanning technology for breast reconstruction and other body scanning applications

Summary

A UK based university has developed a low cost 3D scanning technology for breast reconstruction professionals and other body scanning applications. The system assists the surgeon in planning the operation and choosing the most suitable implant in order to improve patient outcomes and reduces the necessity for repeat surgery. The university is looking for design partners for technical cooperation agreements in order to advance the product to commercial readiness.




Reference TOUK20150702001

Details

Description

The rising incidence of breast cancer has created an increased demand for all forms of breast cancer surgery, including breast reconstruction. To plan reconstruction and choose the breast implant, the surgeon relies on a standard set of manual measurements taken on the patient. This approach does not allow an accurate reconstruction of breast shape and volume, and asymmetries often arise after surgery. In the UK, one in six reconstruction patients were readmitted for repeat surgery. Research at this UK based university has developed a relatively low cost 3D scanning system based on an array of commercially available depth cameras and unique software that calibrates the system and provides accurate data outputs. The system has been trialled successfully with a consultant surgeon at a UK hospital and allows simple, inexpensive 3D surface imaging of the breast region to further the accuracy of forming true to life implants. The university is looking for medical device design partners for technical cooperation agreements in order to advance the product to commercial readiness. Partners with medical regulatory awareness from previous projects in the healthcare field and with links to hospitals/public health bodies for testing and evaluation purposes would be beneficial. The system has other potential market applications such as in sports and biomechanics to monitor obesity or the success of any intervention or in face scanning, for example in orthodontics. Hence, the university is also very interested in developing the system in other health and wellbeing related applications where body morphology and analysis of body shape is important but prohibited by the

Ref: TRUK20140602001 of 19


cost and complexity of current 3D surface imaging systems.


Benefits: - Improve breast reconstruction outcomes - Simple, inexpensive, 3D surface scanning - Improves accuracy and reduces the need for extra surgery - Supports pre-operative planning - Enables post-operative evaluation - No need for special training requirements - Improves patient satisfaction and quality of life - Good value for money


Available for demonstration

IPR Status

Copyright

Profile Origin

Other

Keywords

Technology

006001003 Clinical Research, Trials


006001008 Environmental Medicine, Social Medicine, Sports Medicine

006001013 Medical Research

006001018 Surgery

Market


005001002 Medical imaging

005001007 Other

005005 Anatomy, Pathology, Immunology, Physiology

005007003 Surgical instrumentation and equipment

NACE

Q.86.1.0 Hospital activities

Q.86.9.0 Other human health activities

Ref: TRUK20140602001 of 19


Dissemination


Healthcare

Client


University

Year Established

0


No.

Languages Spoken

English

Client Country

United Kingdom

Partner Sought


Type of partner sought - SME or larger company Specific area of activity of the partner - medical device or product design/development companies with links to hospitals/public health bodies to facilitate testing and evaluation. Task to be performed by the partner sought - evaluate technology with a view to considering technical cooperation agreements.


License agreement Technical cooperation agreement

Ref: TRUK20140602001 of 19


Technology Offer

New lentiviral vector for optimization of advanced therapies and control of cellular processes

Summary

A Spanish public research organization has developed a product based on the application of a lentiviral vector with self-limited regulated expression. It can be used in cellular processes and advanced therapies, especially those in which cell differentiation is required. They are looking for licensees for patent application working in human and animal pharmaceutical fields interested in a licensing or research collaboration agreement for further development of the technology.

Creation Date 13 May 2015



Reference TOES20150428001

Details

Description

The Spanish Public Research Organization has developed a product based on the application of a lentiviral vector whose expression is regulated in an endogenous, self-limited fashion. This characteristic provides the product with an increased level of biosafety and specificity. Once applied, the product triggers the process of interest (e.g. cell differentiation), which subsequently leads to product removal from host cell. High effectivity and biosafety of this product have been already validated in an application developed for its use in pathologies which involve bone mass defects. Current applications in advanced therapies and control of cellular processes often show limitations in efficacy and/or biosafety. This is frequently due to the presence of vector fragments into DNA of host cell. Likewise, a sustained activation of diverse cellular processes usually leads to further control and biosafety issues. The developed product significantly increases the efficacy and biosafety of the process or treatment in an endogenously-regulated manner, by taking advantage of intrinsic cell control mechanisms. They are looking for licensees, mainly in human and animal pharmaceutical fields for a licensing or research collaboration agreement for further development of the technology.


Competitive advantages: - Significant increase in product biosafety, as a result of its regulation design. - Versatility: potentially suitable for a variety of pathologies, therapies and cellular processes


Ref: TRUK20140602001 of 19


Under development/lab tested

IPR Status

Patent(s) applied for but not yet granted


Patent application in January 2015

Profile Origin

National R&D programme

Keywords

Technology

006001004 Cytology, Cancerology, Oncology

006001016 Pharmaceutical Products / Drugs

006001027 Stem cell Technologies

Market

005002001 Therapeutic services

005005 Anatomy, Pathology, Immunology, Physiology

005006002 Oncology

005006005 Surgery and Anaesthesiology

NACE

M.72.1.1 Research and experimental development on biotechnology

Dissemination


Healthcare

Client


R&D Institution

Year Established

0


Ref: TRUK20140602001 of 19


No.

Languages Spoken

English Spanish

Client Country

Spain

Partner Sought


They are seeking licensees for patent application or interested in a licensing or research collaboration agreement for further development of the technology or its extension to other applications. The offer is of interest preferentially in human and animal pharmaceutical fields. The product may be especially useful in traumatology, stomatology, maxillofacial surgery, inflammatory processes and oncology. Furthermore, given biosafety and versatility features of the product, it could be readily applied in other disease areas.


License agreement Research cooperation agreement

Ref: TRUK20140602001 of 19


Technology Offer

Bone density assessment technology for healthcare applications

Summary

A UK University has developed a technology which assesses bone mineral density (BMD) efficiently and with improved patient care and experience. The developed device is highly cost effective and can be applied to various age groups. It can be operated with basic training. The device can also be used to screen for bone fractures. The university is seeking healthcare/medical device companies to further develop the product specification and design through a technical cooperation agreement.

Creation Date 17 June 2015



Reference TOUK20150617001

Details

Description

The gold standard for measuring BMD for fragile or fractured bones is dual energy x-ray absorptiometry (DXA). However, DXA has some limitations. There is limited normative DXA data for children below 5 year old and scans can be difficult to undertake because of positioning and movement. DXA scan is costly and requires the expertise of a radiographer and a radiologist. The principle operation of the new device is integration of digital signal processing and electronics to record low frequency vibration from the bone. The system is portable and computer controlled. It induces the required vibration and records, displays, stores and analyses the bone vibrations responses. Potential applications includes: point of care, early diagnosis, monitoring of a fracture/condition/impact of BMD medication, scene of accident diagnosis, Osteogenesis Imprefecta (OI) or Brittle Bone Disease, Osteoporosis, Veterinary applications, Helping with detection of child abuse (regular bone fractures in children could be due to abnormal BMD or mistreatment. Excluding abnormal BMD strengthen the case for abuse). The university is seeking healthcare/medical device companies to further develop the product specification and design through a technical cooperation agreement.


While existing densitometry methods have their own individual limitations for assessing BMD in infants, this new technique is potentially a novel, non-invasive, accurate and rapid assessment system to assess BMD and screen bone fractures. The device can also be used to screen for bone fracture because vibration of a fractured bone differs from that of sprain.


Ref: TRUK20140602001 of 19


Prototype available for demonstration

IPR Status

Secret Know-how

Profile Origin

Other

Keywords

Technology


006001014 Medical Technology / Biomedical Engineering

006001022 Physiotherapy, Orthopaedic Technology

Market

005001009 Other diagnostic

005001014 Forensic science

005007004 Medical instruments

005007005 Diagnostic equipment

NACE

M.72.1.9 Other research and experimental development on natural sciences and engineering

Dissemination


Healthcare

Client


University

Year Established

0


No.

Languages Spoken

Ref: TRUK20140602001 of 19


English

Client Country

United Kingdom

Partner Sought


Type: SMEs and/or Large companies Area of activity; healthcare and medical devices Role: further develop the product specifications and design, including certification and other regulatory support


Technical cooperation agreement

Ref: TRUK20140602001 of 19


Technology Offer

Licensing of uniform stable isotope labelling technology for discovery and quantification of biomarkers, drug

development and design

Summary

A Dutch SME developed a uniform stable isotope labelling technology for obtaining biomolecules of various complexity for nano-biotechnological applications. It also allows cost-effective preparation of labelled biomolecules in insect and mammalian cell lines. This technology can be used for quantification, for investigation of metabolic pathways and for 3D structure determination of drug targeting within drug design and discovery. The company offers a license agreement and seeks R&D cooperation.




Reference TONL20150630001

Details

Description

In cooperation with Universities this Dutch SME has developed a uniform labelling technology for stable- (non radio active) isotope labelling. The technology can be applied in many fields. This company focusses on: quantification tools for biomarkers, drug discover and drug design, development of novel nutrition strategies. The company has broad expertise in development of specific labelling schemes for preparation of biomolecules labelled with stable isotopes from various sources (archaea, bacteria, algae, yeast, insect cell lines, mammalian cell lines). The track records include stable-isotope-labelled amino acids, peptides, proteins, lipids (fatty acids, sterols, pigments), human receptors (such as histamine 1 receptor), cell extracts and other products. These products were isolated from various labelled cells that were obtained through specifically designed proprietary labelling schemes. The use of the products is broad, starting from characterisation of purified biomolecule within fundamental research, study of ligand-protein interaction (using either the labelled ligand or the labelled protein) up to application of labelled cell extracts as either cell culture media components for cell culture medium design or as a quantification tools. The detection methods for stable isotopes are Nuclear Magnetic Resonance (NMR) spectroscopy, Fourier Transform Infrared spectroscopy (FT-IR), Mass spectrometry (MS). The combination of the offered labelling technology with the detection methods could be beneficial for both the new applications of labelled products and new developments in detection equipment.

Ref: TRUK20140602001 of 19


A few application fields: - Metabolomics and proteomics: In respect to the metabolomis and proteomics tools the company offers stable-isotope-labelled cells for the preparation of standards. - Metabolic pathways: Foods are digested, absorbed and distributed in the body. Foods contain macronutrients (carbohydrates, lipids and proteins) and micronutrients (e.g. vitamins, minerals, trace elements). These nutrients induce changes at Ribonucleic acid (RNA), protein and metabolite level in the receiving cell or organism. The profiling technologies such as transcriptomics (gene expression analysis), proteomics (protein expression analysis) and metabolomics (metabolite profiling) are applied to better understand and assess effect of nutrients. Stable-isotope labelling of nutrients supports these studies. - Drug discovery and design: Drug discovery and design. In respect to drug discovery and drug design, the company proposes a multidisciplinary approach to resolve 3D structure of drug target complex that requires the following: a) large scale membrane protein (drug target) production, b) stable isotope labelling, c) development of solid-state nuclear magnetic resonance (ssNMR) and Fourier transform infrared spectroscopy (FTIR) methodology for measurements of drug-drug target interactions and structural analysis. The company approaches this along the following experimental lines A-E and contributes with the labelling aspect. A. Functional large scale expression and purification. B. Stable-isotope labelling of ligands and receptors. C. FT-IR studies to probe secondary structure and ligand induced conformational changes. D. ssNMR studies to probe ligand conformation and ligand-protein cross-talk. E. Molecular modelling. The company is looking for partners that could benefit from this technology and is looking for cooperation in the framework of a license agreement and joint development of new products or applications: - Out-licensing of proprietary technology to label biomolecules with stable isotopes (such as 13C and 15N); - Joint R&D to develop novel quantification tools; - Development personalized nutritional strategies; - Development of tracers and internal standards based from whole cells of organisms (archaea, bacteria, eukaryotes); - Omics approaches based on stable-isotope labelling.


This technology is addressing: - availability of molecules with high level of enrichment with stable isotopes (for 13C higher than 98% and for 15N higher than 98%); - cost-effective aspects; these aspects are mainly related to the development of cell culture media for insect cell lines and mammalian cell lines that allows obtaining stable isotope labelled biomolecules for various applications; - 1 sample only will answer different questions; this is achieved by uniform labelling (where each atom of the molecule is enriched with a stable isotope, such as 13C and/or 15N ), therefore there is no need to obtain several samples with a variety of labelling positions; - ‘from source to product’, this means that based on specific needs of the customer the company

develops stable-isotope labelled biomolecules via biosynthetic route in order to obtain molecules of interest labelled with stable isotopes. - “biosynthesis versus chemical synthesis”, availability of the required stable isotope labelled

molecule via biosynthesis, price comparison with obtaining of the same molecule via chemical synthesis; often biosynthetic way is the only possible way to obtain biomolecule.

Ref: TRUK20140602001 of 19



Already on the market

IPR Status

Patents granted


Patents are granted in Europe (The Netherlands, UK, Switzerland, Germany, France, Belgium), Russian Federation, Canada, Australia and Japan.

Profile Origin

National R&D programme

Keywords

Technology

006002001 Biochemistry / Biophysics

006002002 Cellular and Molecular Biology

006002006 Microbiology

006002010 Enzyme Technology

006002012 Protein Engineering

Market

004006 Microbiology

004012 Cellular and Molecular Biology

004016 Enzymology/Protein Engineering/Fermentation


005001002 Medical imaging

NACE

M.72.1.1 Research and experimental development on biotechnology

Dissemination


Bio Chem Tech

Ref: TRUK20140602001 of 19


Client


Industry SME <= 10

Year Established

2000

Turnover

<1M


Yes

Languages Spoken

English Dutch Russian

Client Country

Netherlands

Partner Sought


The partner this company is looking for is active in either of the fields: - biomarkers, - omics quantification tools, - metabolic studies and profiling, - structure-function studies, - drug discovery and design (Nuclear Magnetic Resonance (NMR) structure determination), - nutritional strategies. These companies are offered a license agreement or are invited to enter into research cooperation with the Dutch company.

Type and Size of Partner Sought

SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500


License agreement Research cooperation agreement

New pediatric diagnostic and therapeutic procedure · cancer surgery, including breast...

Documents

Transcript of New pediatric diagnostic and therapeutic procedure · cancer surgery, including breast...